Search PubMed⌕ Search

Biomedical subjects

C Nowak

Publications and source records attributed to C Nowak.

At least 73 records · Page 4Linked to original sources
PubMed1980

Recent results with clinically used antineoplastic drugs and drug combinations in vivo.

Using four mouse tumor systems--leukemia L1210, i.m. mammary carcinoma 1142A, Lewis lung carcinoma, metastatic model of the mammary carcinoma 1142A--a combined treatment consisting of vincristine--cyclophosphamide--metrotrexate--5-fluorouracil is superior to a combined treatment with carminomycin--dibromodulcitol. The treatment with carminomycin and dibromodulcitol in each case alone causes therapeutic benefits being superior to a treatment with the combination carminomycin--dibromodulcitol. This result could be stated for all tumor systems used. Carminomycin showed the greatest effectivity against the leukemia L1210. A human tumor nude mouse system--ascitic mesothelioma 1503A--is presented which is suitable for chemotherapeutic experiments. First test results indicated an antineoplastic effectivity after daunoblastin treatment, but cyclophosphamide and carminomycin did not influence the life span.

Animals↗
PubMed1980

[Therapeutic effectiveness of carminomycin (CRM) in combination with dibromodulcitol (DBD) compared with the combination vincristine, cyclophosphamide, methotrexate, 5-fluorouracil (VCMF) on some tumor systems (author's transl)].

The antineoplastic effectivity of VCMF was compared with the combined therapy CRM plus DBD in the mouse tumor systems L1210, 1142 A and Lewis lung carcinoma. Therapy of tumor-bearing mice was carried out by administering doses on the basis of LD 10 or with doses directly calculated from the clinical study CMEA 0102. In the most of all experiments VCMF was superior to the combination CRM plus DBD.

Animals↗
PubMed1979

[Studies on biological characterization of mammary tumours of the Sprague-Dawley-rat in the syngeneic tumour-host system. III. Metastatic experiments with primary tumours, transplantation passages and metastatic cells (author's transl)].

The metastatic spread following intravenous application of cells from primary and transplanted mammary carcinomas is described. When using cells from primary tumours the incidence rate was between 0 and 17%, but was much higher in the case of advanced tumours (transplantation passages and metastases).

Animals↗